HomeFUNDING

FUNDING

R3 Vascular Inc. Completes Series A Financing Round and New Chief Executive Officer

The company reports the proceeds will support the company's clinical trial work in developing a next generation of below-the-knee (BTK) interventional therapies for PAD. 

HDT Bio Announces Completion of Seed Financing Round

The vaccine is slated to enter clinical trials in Q4 2020 in partnership with the NIH/NIAID.

HomeDoctor Raises €3,7m Series A Funding Led by Cogito Capital Partners

HomeDoctor, founded in 2016, is a leader in the Polish market in providing online medical consultations and delivery of healthcare services to patients’ homes.

Synklino ApS Raises Seed Round to Develop Breakthrough Infection Treatment for Transplant Patients

The company is a spinout from the University of Copenhagen and the Technical University of Denmark established to develop groundbreaking therapies against devastating viral infections.

Hyprevention Raises New Financing to Commercialize Spinal Implant Product V-STRUT© in the USA

Hyprevention CEO Cecile Vienney notes, “We are delighted that our existing investors have shown confidence in our product development efforts and commercialization plans for the US market by increasing their investment in the company."

ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital

This round of financing will be exclusively funded by Shanghai Healthcare Capital ("SHC"), managed by SIIC Capital, where Shanghai Pharma is one of the founding strategic cornerstone LPs.

Pressao Medical Completes Funding

The company has two products under development. The first is BP-ADJUST™, a new device in the form of a wristwatch that monitors blood pressure and heart rate and uses the information to deliver unique energy therapy to control BP. The second product is BP-ADJUST™ CV.

RapidAI Announces $25 Million in Series B Funding – Funds to Accelerate the Company’s Growth Globally

Founded in 2011, RapidAI makes the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials. This funding will support the continued advancement of the Rapid® platform and world-class clinical products.

LAVA Therapeutics Announces $83 million Series C Financing

As part of the transaction, Nanna Lüneborg, partner at Novo Ventures, Laia Crespo, EU head of investments at Sanofi Ventures, and Joël Jean-Mairet, managing partner and co-founder of Ysios, joined LAVA as members of the board of directors.